The new Inhibrx will also start with $200 million in funding from the French drugmaker. AATD is an inherited disorder whose primary consequence is life-threatening pulmonary emphysema, resulting ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

The problem of the pathophysiology of unstable angina lies in patients who have milder and persistent rest pain over months or even years. The perception is that these cases are related to vasomotor ...

The increased knowledge and capability for diagnosis improved the growth of the Alpha-1 Antitrypsin Deficiency (AATD) market. Treatment advancements, such as augmentation therapy and gene-based ...